{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T11:41:40Z","timestamp":1782042100908,"version":"3.54.5"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>While higher infliximab (IFX) trough concentrations (TCs) are associated with better outcomes in patients with inflammatory bowel disease (IBD), they could pose a risk for adverse events (AEs), including IFX\u2010induced skin lesions. Therefore, we studied correlations between IFX TCs and occurrence of AEs in paediatric IBD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this single\u2010centre study, all children with Crohn's disease (CD) and ulcerative colitis (UC) receiving IFX maintenance therapy who underwent proactive drug monitoring between March 2015 and August 2022 were included. IFX doses\/intervals\/TCs and patient characteristics were systematically registered, as well as AEs and skin lesions appearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 109 patients (72 CD and 37 UC) contributed 2913 IFX TCs. During a median follow\u2010up of 3.0 [1.5\u20134.5] years, we observed 684 AEs in 101 patients and 49 skin lesions in 35 patients. There was no significant difference (<jats:italic>p<\/jats:italic>\u2009=\u2009.467) in median TCs between patients with and without skin lesions. However, higher median IFX doses were associated with an increased hazard rate of skin lesions [HR 1.084 (1.024\u20131.148), <jats:italic>p<\/jats:italic>\u2009=\u2009.005], in addition to female sex [2.210 (1.187\u20135.310), <jats:italic>p<\/jats:italic>\u2009=\u2009.016] and diagnosis of CD [1.695 (1.241\u20131.877), <jats:italic>p<\/jats:italic>\u2009=\u2009.011]. Considering IFX therapeutic TC cut\u2010offs of 5.0 and 9.0\u2009\u00b5g\/mL, there was no significant difference in AE rate (<jats:italic>p<\/jats:italic>\u2009=\u2009.749 and <jats:italic>p<\/jats:italic>\u2009=\u2009.833, respectively). Also, no significant association between IFX doses and AE rate (<jats:italic>p<\/jats:italic>\u2009=\u2009.159).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Increasing the IFX dose to achieve therapeutic TCs may not increase the overall risk of AEs in paediatric IBD patients. However, concerns arise regarding the risk of skin lesions, especially in female CD patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jpn3.12066","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T07:01:10Z","timestamp":1702710070000},"page":"95-104","source":"Crossref","is-referenced-by-count":4,"title":["Identifying risk factors of anti\u2010TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease"],"prefix":"10.1002","volume":"78","author":[{"given":"Karen","family":"van Hoeve","sequence":"first","affiliation":[{"name":"Department of Paediatric gastroenterology &amp; Hepatology &amp; Nutrition University Hospitals Leuven, KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debby","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hillary","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospitals Leuven, KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Paediatric gastroenterology &amp; Hepatology &amp; Nutrition University Hospitals Leuven, KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.11.026"},{"key":"e_1_2_11_4_1","article-title":"The medical management of paediatric crohn's disease: an ECCO\u2010ESPGHAN guideline update","author":"Rheenen PF","year":"2020","journal-title":"J Crohns Colitis"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002035"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1413090"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001231"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002265"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.08.079"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002486"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002304"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv159"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0729"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv116"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/428702"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00042"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1666914"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.03.018"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy066"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz264"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.205"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003240"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000624"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy111"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000239"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21493"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.143"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20867"},{"key":"e_1_2_11_30_1","unstructured":"Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published online November 27 2017. Accessed September 2 2022.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003044"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-017-0267-8"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.89"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.04.012"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy390"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.218"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3763-0"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy112"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420917387"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac055"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002349"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000757"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4921-y"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.07.022"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000088"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04866.x"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302853"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13352"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000342"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05082.x"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.12066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T03:06:40Z","timestamp":1712545600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.12066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/jpn3.12066"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.12066","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,10]]}}}